The use of artificial intelligence (AI) has the potential to reshape many aspects of the health care systems in Canada, from streamlining documentation and workflows to improving how conditions are diagnosed and tailoring treatments plans.
The 2025 Watch List, published by Canada’s Drug Agency,…
New Watch List Spotlights Advances and Issues in Artificial Intelligence Use in Canadian Health Care
The US-based Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) have selected the first research topic for the Health Economics Methods Advisory (HEMA) group: an assessment of the benefits of…
Today, for the 2nd year running Canada’s Drug Agency was named one of the National Capital Region's top employers for 2025.
This special designation recognizes employers in the Ottawa-Gatineau metropolitan area that lead their industries in offering exceptional places to work. Canada’s Drug Agency…
Canada’s Drug Agency is seeking knowledgeable and experienced individuals to join our expert and advisory committees.
Our annual call for nominations is now open for the following positions:
1 patient member on the Canadian Drug Expert Committee (CDEC)
1 expert member on the pan-Canadian Oncology…
On Rare Disease Day — a global event dedicated to raising awareness for the millions of people living with rare diseases — Canada’s Drug Agency has published new pan-Canadian guidance on best practices and standards for rare disease registries (RDRs). The guidance, aligned with international…
Leaders of 3 health technology assessment organizations convene working group and steering committee to critically and independently research new health economic methods
The USA-based Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence (…
The 2025 call for nominations to join expert and advisory committees at Canada’s Drug Agency will be open from March 3 to March 31, 2025.
These committees play a critical role in our efforts to power evidence-informed drug and health technology decisions and improve health outcomes for…
The nomination period is now closed
Canada’s Drug Agency has officially opened its call for nominations for the position of Chair of its Board of Directors. This is a unique opportunity to help shape how evidence is used to power decisions about drugs and health technologies and improve…
Recommendations will help organizations that appraise new drugs establish whether their use will result in longer-term benefits for patients
Four health technology assessment agencies, including Canada’s Drug Agency, have published new guidance on the use of surrogate endpoints in cost-…
Canada’s Drug Agency is seeking to expand the group of scientists who contribute their expertise to our organization and help us power evidence-informed health technology decisions.
Within our organization, there is a need for timely access to skills that can supplement our existing capacity and…
Consultation status: ClosedConsultation period: January 6 to February 6, 2025
Canada’s Drug Agency is outlining additional plans to modernize the drug reimbursement review process and is seeking feedback on our proposed approaches.
The consultation document, Proposed Improvements to the Drug…
Canada's Drug Agency (CDA-AMC) and the Canadian Institute for Health Information (CIHI) have signed a 3-year agreement that will leverage the strengths of both organizations to build a stronger drug data and analytics foundation across Canada. This work will aim to advance CIHI’s Pharmaceutical…